ASMB vs. NKTR, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRX
Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry.
Assembly Biosciences vs.
Assembly Biosciences (NASDAQ:ASMB) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
Assembly Biosciences has a net margin of -144.05% compared to Nektar Therapeutics' net margin of -180.70%. Assembly Biosciences' return on equity of -121.46% beat Nektar Therapeutics' return on equity.
Assembly Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
Assembly Biosciences has higher earnings, but lower revenue than Nektar Therapeutics.
Nektar Therapeutics received 391 more outperform votes than Assembly Biosciences when rated by MarketBeat users. Likewise, 70.84% of users gave Nektar Therapeutics an outperform vote while only 58.84% of users gave Assembly Biosciences an outperform vote.
Assembly Biosciences presently has a consensus price target of $35.00, indicating a potential upside of 183.40%. Nektar Therapeutics has a consensus price target of $4.08, indicating a potential upside of 338.03%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Assembly Biosciences.
In the previous week, Nektar Therapeutics had 4 more articles in the media than Assembly Biosciences. MarketBeat recorded 6 mentions for Nektar Therapeutics and 2 mentions for Assembly Biosciences. Nektar Therapeutics' average media sentiment score of 0.71 beat Assembly Biosciences' score of 0.56 indicating that Nektar Therapeutics is being referred to more favorably in the news media.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Nektar Therapeutics beats Assembly Biosciences on 11 of the 17 factors compared between the two stocks.
Get Assembly Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assembly Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ASMB) was last updated on 2/22/2025 by MarketBeat.com Staff
